Niagen Bioscience, Inc. (NAGE)

↓ Download CSV

CIK 0001386570 · Nasdaq · Medicinal Chemicals & Botanical Products

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Niagen Bioscience, Inc. reported revenue of $129.42M, up 29.9% from the prior year. The company was profitable, with a net margin of 13.4% and a gross margin of 64.3%. It held $106.41M in total assets against $29.87M in total liabilities.

Key ratios (FY2025)

64.3%
Gross margin
12.6%
Operating margin
13.4%
Net margin
22.7%
Return on equity
+29.9%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$129.42M$99.60M$83.57M$72.05M$67.45M$59.26M$46.29M$31.56M$21.20M
Cost of Revenue$46.23M$38.01M$32.79M$29.25M$25.96M$23.98M$20.52M$15.50M$10.72M$11.27M
Gross Profit$83.19M$61.59M$50.78M$42.80M$41.49M$35.27M$25.77M$16.05M$10.48M$10.39M
Operating Income$16.28M$7.73M-$5.60M-$18.63M-$27.07M-$19.85M-$31.30M-$33.17M-$16.38M-$2.91M
Net Income$17.38M$8.55M-$4.94M-$16.54M-$27.13M-$19.93M-$32.15M-$33.32M-$11.38M-$2.93M
EPS (Diluted)$0.20$0.11$-0.07$-0.24$-0.40$-0.33
Total Assets$106.41M$68.28M$54.96M$54.06M$57.84M$38.36M$40.25M$42.23M$62.72M$19.75M
Total Liabilities$29.87M$22.18M$26.51M$25.39M$26.11M$21.93M$19.80M$15.05M$8.89M$9.78M
Shareholders' Equity$76.53M$46.09M$28.46M$28.67M$31.73M$16.42M$20.45M$27.18M$53.83M$9.97M
Cash & Equivalents$44.50M$27.20M$20.30M$28.22M$16.70M$18.81M
Operating Cash Flow$13.50M$12.11M$7.12M-$15.10M-$24.16M-$10.60M-$20.44M-$20.91M-$9.80M-$2.94M
Capital Expenditures$743.0K$1.32M$1.17M$1.50M
Shares Outstanding79.71M77.33M74.98M74.57M68.13M61.88M59.56M55.1K54.70M37.54M